Menu
Recruiting NCT07441499

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

— Observational Urothelial Carcinoma (UC) Bladder (Urothelial, Transitional Cell) Cancer Liquid Biopsy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Multi-Component Liquid Biopsy for Urothelial Carcinoma.
Who it may be relevant to
Registry conditions: Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma

Interventions

  • Diagnostic test Multi-Component Liquid Biopsy for Urothelial Carcinoma
    This intervention is a non-invasive, multi-component liquid biopsy assay specifically designed for patients with urothelial carcinoma (including bladder cancer and upper tract urothelial carcinoma). It integrates multiple tumor-derived analytes from paired blood and urine samples: circulating cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) from peripheral blood plasma, urinary tumor DNA (utDNA)/cell-free DNA from urine, exosomal RNAs (e.g., miRNAs, lncRNAs) and proteins from urine-derived ex

Primary outcome measures

  • Diagnostic Concordance [Time frame: At baseline (pre-treatment/diagnosis confirmation) or within the diagnostic window.]
Secondary outcome measures (1)
  • Dynamic concordance during treatment/follow-up [Time frame: Serial assessments at baseline, during treatment (e.g., after each cycle or at predefined intervals such as 4-8 weeks), post-treatment (e.g., 3, 6, 12 months, and annually thereafter), up to 24-36 months or until progression/recurrence]

Eligibility criteria

Inclusion criteria

  • Suspected or histologically confirmed urothelial carcinoma

Exclusion criteria

  • History of or concurrent active malignancy other than urothelial carcinoma

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • The second hospital of Tianjin Medical University — Tianjin

Identifiers

NCT: NCT07441499 · Truce-LBX

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗